Bioventix PLC (LON:BVXP - Get Free Report) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 2,672.69 ($36.16) and traded as high as GBX 2,850 ($38.56). Bioventix shares last traded at GBX 2,800 ($37.88), with a volume of 2,136 shares trading hands.
Bioventix Stock Performance
The firm has a market cap of £145.05 million, a PE ratio of 17.92 and a beta of 0.35. The firm has a fifty day simple moving average of GBX 2,680.09 and a two-hundred day simple moving average of GBX 2,979.47.
Bioventix (LON:BVXP - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.98) earnings per share for the quarter. Bioventix had a return on equity of 69.09% and a net margin of 59.51%. Equities analysts forecast that Bioventix PLC will post 166.3066955 EPS for the current fiscal year.
Bioventix Cuts Dividend
The company also recently declared a dividend, which was paid on Friday, April 25th. Shareholders of record on Thursday, April 10th were issued a dividend of GBX 70 ($0.95) per share. This represents a yield of 2.95%. The ex-dividend date was Thursday, April 10th. Bioventix's dividend payout ratio is presently 102.19%.
Insider Buying and Selling at Bioventix
In related news, insider Bruce Hiscock bought 31 shares of the company's stock in a transaction dated Monday, April 28th. The stock was purchased at an average price of GBX 2,632 ($35.61) per share, for a total transaction of £815.92 ($1,103.79). 8.02% of the stock is currently owned by company insiders.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
See Also
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
